CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

SF12, EQ-5D-5L and work status standardized quantitative assessmentsWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug718 Data Collection: Clinical Care Assessments Wiki 1.00
drug349 Biological sample collection Wiki 0.71

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 COVID-19 - Quality of Life After Infection

This study aims to investigate the quality of life of COVID-19 patients after recovery and discharge from the hospital. Patients following-up at the PWH outpatient clinics will be enrolled for further evaluation via telephone follow-up at one, three, and six months after hospital discharge. SF12, EQ-5D-5L and work status standardized quantitative assessments of quality of life will be implemented via telephone follow-up at these time-points. Previous studies of patients infected with SARS-CoV-1 in 2003 at PWH showed that significant numbers of recovering patients had impaired long-term health status. It is important to see if these same problems also afflict patients infected with the SARS-CoV-2 virus (the novel coronavirus which causes COVID-19).

NCT04377464 COVID-19 Quality of Life Other: SF12, EQ-5D-5L and work status standardized quantitative assessments

Primary Outcomes

Description: The primary outcome measure will be the health summary scores from Short Form Health Survey version 2 Hong Kong (SF-12v2(HK)) in COVID patients at six-months post-discharge from hospital.

Measure: Six-month SF-12v2(HK) Scores

Time: July 1, 2020-January 31, 2021

Secondary Outcomes

Description: The secondary outcome measures will include the health status measures of the EuroQuality of Life Five Dimensions (EQ-5D-5L) at six-months.

Measure: Six-month EQ-5D-5L Scores

Time: July 1, 2020-January 31, 2021

Description: The secondary outcome measures will include the health status measures of the Short Form Health Survey version 2 Hong Kong (SF-12v2(HK)) at one-month.

Measure: One-month SF-12v2(HK)

Time: July 1, 2020-January 31, 2021

Description: The secondary outcome measures will include the health status measures of the EuroQuality of Life Five Dimensions (EQ-5D-5L) at one-month.

Measure: One-month EQ-5D-5L Scores

Time: July 1, 2020-January 31, 2021

Description: The secondary outcome measures will include the health status measures of the Short Form Health Survey version 2 Hong Kong (SF-12v2(HK)) at three-months.

Measure: Three-month SF-12v2(HK) Scores

Time: July 1, 2020-January 31, 2021

Description: The secondary outcome measures will include the health status measures of the EuroQuality of Life Five Dimensions (EQ-5D-5L) at three-months.

Measure: Three-month EQ-5D-5L Scores

Time: July 1, 2020-January 31, 2021

Description: Return to work status in COVID patients at one, three and six-months post discharge from hospital.

Measure: One, Three and Six-month Return to Work Status

Time: July 1, 2020-January 31, 2021

No related HPO nodes (Using clinical trials)